CSS
NTLA icon

Cubist Systematic Strategies’s Intellia Therapeutics NTLA Stock Holding History

Cubist Systematic Strategies’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.76M Buy
+102,051
New +$1.26M 0.01% 1634
2024
Q4 		– Sell
-188,316
Closed -$3.87M – 3369
2024
Q3 		$3.87M Buy
+188,316
New +$4.34M 0.02% 992
2024
Q2 		– Sell
-23,159
Closed -$637K – 3702
2024
Q1 		$637K Buy
23,159
+4,117
+22% +$114K ﹤0.01% 2476
2023
Q4 		$581K Sell
19,042
-4,794
-20% -$138K ﹤0.01% 2441
2023
Q3 		$754K Buy
+23,836
New +$925K 0.01% 2066
2023
Q2 		– Sell
-117,395
Closed -$4.38M – 4049
2023
Q1 		$4.38M Sell
117,395
-53,756
-31% -$2.11M 0.03% 1043
2022
Q4 		$5.97M Buy
171,151
+83,784
+96% +$3.98M 0.03% 864
2022
Q3 		$4.89M Buy
87,367
+279
+0.3% +$17.3K 0.03% 1092
2022
Q2 		$4.51M Buy
87,088
+75,499
+651% +$3.83M 0.03% 1082
2022
Q1 		$842K Buy
+11,589
New +$982K 0.01% 2172
2021
Q4 		– Sell
-20,830
Closed -$2.79M – 3571
2021
Q3 		$2.79M Buy
20,830
+1,733
+9% +$262K 0.04% 796
2021
Q2 		$3.09M Buy
19,097
+16,741
+711% +$1.3M 0.03% 811
2021
Q1 		$189K Sell
2,356
-42,807
-95% -$2.87M ﹤0.01% 2495
2020
Q4 		$2.46M Sell
45,163
-1,495
-3% -$54.3K 0.03% 821
2020
Q3 		$928K Sell
46,658
-13,541
-22% -$282K 0.01% 1384
2020
Q2 		$1.26M Buy
+60,199
New +$1.02M 0.02% 1053
2019
Q2 		– Sell
-10,023
Closed -$171K – 2547
2019
Q1 		$171K Sell
10,023
-43,646
-81% -$651K 0.01% 1852
2018
Q4 		$733K Buy
53,669
+48,175
+877% +$895K 0.03% 723
2018
Q3 		$157K Sell
5,494
-7,159
-57% -$208K 0.01% 1483
2018
Q2 		$346K Buy
12,653
+709
+6% +$17.2K 0.02% 993
2018
Q1 		$252K Buy
+11,944
New +$294K 0.01% 1262

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's NTLA Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Intellia Therapeutics (NTLA) in Q3 2025: 102,051 shares worth $1.76M. The stake represents 0.01% of the portfolio and ranks #1634 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in NTLA as recently as Q3 2024.

Cubist Systematic Strategies first reported a position in NTLA in Q1 2018 and has held it in 21 quarters since. The position peaked at $5.97M in Q4 2022. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Cubist Systematic Strategies held 102,051 shares of Intellia Therapeutics worth $1.76M as of Q3 2025.
  • Intellia Therapeutics was a new Cubist Systematic Strategies position in Q3 2025.
  • Intellia Therapeutics made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1634 holding.
  • Cubist Systematic Strategies first reported a position in Intellia Therapeutics in Q1 2018 and has held it in 21 quarters since.
  • Cubist Systematic Strategies's Intellia Therapeutics position peaked at $5.97M in Q4 2022.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.